

RECEIVED  
CENTRAL FAX CENTER


001

DEC 19 2005

## CERTIFICATE OF FACSIMILE TRANSMISSION UNDER 37 C.F.R. §1.8

I hereby certify that this correspondence, totaling 16 pages including recited attachments, is being facsimile transmitted to the United States Patent and Trademark Office at facsimile no.: 571-273-8300 (Central number) on the below date:

Date: December 19, 2005 Name: Ashley L. Rhoades

Signature: BRINKS  
HOFER  
GILSON  
& LIONE

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: Henrik Sonderskov Klint

Appln. No.: 10/615,510

Filed: July 7, 2003

For: ENDOVASCULAR MEDICAL DEVICE  
WITH PLURALITY OF WIRES

Attorney Docket No: 8627-227

Examiner:

Art Unit: 3763

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

## TRANSMITTAL

Sir:

## Attached is/are:

Supplemental Information Disclosure Statement; Form PTO-1449; copy of required reference  
 Return Receipt Postcard

## Fee calculation:

No additional fee is required.  
 Small Entity.  
 An extension fee in an amount of \$\_\_\_\_\_ for a \_\_\_\_\_-month extension of time under 37 C.F.R. § 1.136(a).  
 A petition or processing fee in an amount of \$\_\_\_\_\_ under 37 C.F.R. § 1.17(\_\_\_\_).  
 An additional filing fee has been calculated as shown below:

	Claims Remaining After Amendment	Highest No. Previously Paid For	Present Extra	Rate	Small Entity		Not a Small Entity	
					Add'l Fee	or	Rate	Add'l Fee
Total		Minus		x \$25=			x \$50=	
Indep.		Minus		x 100=			x 200=	
First Presentation of Multiple Dep. Claim				+\$180=			+\$360=	
				Total	\$		Total	\$

## Fee payment:

A check in the amount of \$\_\_\_\_\_ is enclosed.  
 Please charge Deposit Account No. 23-1925 in the amount of \$\_\_\_\_\_. A copy of this Transmittal is enclosed for this purpose.  
 Payment by credit card in the amount of \$\_\_\_\_\_ (Form PTO-2038 is attached).  
 The Director is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this paper (including any extension fee required to ensure that this paper is timely filed), or to credit any overpayment, to Deposit Account No. 23-1925.

Respectfully submitted,

December 19, 2005

Date

John H. Beaupre (Reg. No. 54,729)

RECEIVED  
CENTRAL FAX CENTER

002

DEC 19 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: **Henrik Sonderskov Klint**  
 Appln. No.: **10/615,510**  
 Filed: **July 7, 2003**  
 For: **ENDOVASCULAR MEDICAL DEVICE WITH PLURALITY OF WIRES**  
 Attorney Docket No: **8627-227**

Examiner:  
 Art Unit: **3763**

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, and more particularly in accordance with 37 C.F.R. §1.97(b), Applicant hereby cites the following reference(s):

Document Number	Publication Date	Name of Patentee or Applicant
4,811,743	03/14/1989	Stevens
5,662,622	09/02/1997	Gore et al.

Foreign Patent Document	Publication Date	Name of Patentee or Applicant
EP 1 040 843	10/04/2000	William Cook Europe A/S et al.

Applicant is enclosing Form PTO-1449 (one sheet), along with a copy of each listed reference for which a copy is required under 37 C.F.R. §1.98(a)(2). As each of the listed references is in English, no further commentary is believed to be necessary, 37 C.F.R. §1.98(a)(3). Applicant respectfully requests the Examiner's consideration of the above reference(s) and entry thereof into the record of this application.

By submitting this Statement, Applicant is attempting to fully comply with the duty of candor and good faith mandated by 37 C.F.R. §1.56. As such, this Statement is not intended to constitute an admission that any of the enclosed references, or other information referred to therein, constitutes "prior art" or is otherwise "material to patentability," as that phrase is defined in 37 C.F.R. §1.56(a).

BRINKS  
HOFER  
GILSON  
& LIONE

-1-

Appln. No. 10/615,510

Attorney Docket No. 8627-227

Applicant has calculated no fee to be due in connection with the filing of this Statement. However, the Director is authorized to charge any fee deficiency associated with the filing of this Statement to a deposit account, as authorized in the Transmittal accompanying this Statement.

Respectfully submitted,

December 19, 2005  
Date



Jon H. Beaupre (Reg. No. 54,729)

BRINKS  
HOFER  
GILSON  
& LIONE

-2-

RECEIVED  
CENTRAL FAX CENTER

004

DEC 19 2005

FORM PTO-1449	APPLICATION NO.	ATTORNEY DOCKET NO.
	10/615,510	8627-227
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE	GROUP ART UNIT
(use several sheets if necessary)	July 7, 2003	3763
	FIRST NAMED INVENTOR: Henrik Sønderskov Klint	
	EXAMINER NAME:	

EXAMINER INITIALS	Cite No.	DOCUMENT NUMBER Number-Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where, Relevant Passages or Relevant Figures Appear
A1	4,811,743		03/14/1989	Stevens	
A2	5,662,622		09/02/1997	Gore et al.	
A3					
A4					
A5					
A6					
A7					
A8					
A9					
A10					
A11					
A12					
A13					

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS	Cite No.	Foreign Patent Document Country Code, Number-Number- Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where, Relevant Passages or Relevant Figures Appear	T
A14	EP 1 040 843		10/04/2000	William Cook Europe A/S et al.		
A15						
A16						
A17						
A18						

EXAMINER INITIAL	NON PATENT LITERATURE DOCUMENTS (Include name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.)	T
A19		
A20		
A21		
A22		
A23		
A24		

NOTE: For "T" - please place an "X" if an English translation is being provided to the Patent Office.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.